Key facts
- Alveus Therapeutics’s last known valuation is $275.2M (Feb 2026).
- It has raised $202.0M across 1 recorded rounds; the latest was Later Stage VC ($56.9M) in Dec 2025.
- Notable investors include Novo Holdings, Kurma Partners, Andera Partners, Omega Funds, Agent Capital — 13 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Alveus Therapeutics
Funding rounds
1 roundsAbout Alveus Therapeutics
Developer of biological and small-molecule treatments designed for metabolic disease management. The company's platform combines genetic analysis, biological insights, and empirical data to develop dual-acting mechanisms, peptides, antibodies, and small molecules that target cardiometabolic dysfunctions, enabling the healthcare market to address therapeutic gaps in weight maintenance, treatment adherence, quality of weight loss, and long-term metabolic outcomes with reduced overlap.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2023
- Employees
- 28
- Website
- alveustx.com/
- Ownership
- Privately Held (backing)
Alveus Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alveus Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alveus Therapeutics in its N-PORT filings yet. We sweep new filings monthly.